Surmodics’ long-term earnings growth rate is projected at 10%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. Integer Holdings has an expected earnings growth rate of 31.2% for the fourth quarter 2018 and a Zacks Rank #2 (Buy). Some better-ranked stocks in the broader medical space are Integer Holdings Corporation ITGR, Surmodics, Inc. Integra LifeSciences carries a Zacks Rank #4 (Sell). Moreover, consolidation in the industry could lead to intense pricing pressure. The company needs continuous innovation to fend off rivalry. Meanwhile, Integra LifeSciences faces intense competition in the surgical implants and medical instruments market. In the third quarter, the company registered double-digit growth in this franchise, primarily banking on broad-based strength across the portfolio. We are also upbeat about the company’s Regenerative Technologies, the largest franchise under Orthopedics and Tissue Technologies. Turning to Europe, management feels encouraged about the region’s growth potential with respect to Tissue Technologies business and CUSA Clarity product scheduled to be launched in Europe. In line with this strategy, the company is preparing to launch several products in China and Japan. Integra LifeSciences is looking forward to investment opportunities in the Asian market for growing its business much faster than in the United States and also aiding certain parts of its international businesses. Within Orthopedics & Tissue Technologies, international sales rose in mid-single-digits during the last reported quarter, boosted by a solid foothold in Europe. Per Integra LifeSciences, the acquisition of Codman is likely to effectively double the company’s international business within this segment. The same in turn, is offset by slightly soft sales in Europe. International sales within Codman Specialty Surgical have been strong of late, driven by growth in core neurosurgery business and strength in certain key markets such as Japan and Canada. On a positive note, Integra LifeSciences has been successfully growing overseas.
0 kommentar(er)
